| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $357K | — | +0.0% |
| SG&A Expense | $701K | -37.3% | +276.8% |
| Operating Income | -$701K | +37.3% | -29.1% |
| Net Income | -$1.8M | -1709.5% | -203.2% |
| EPS (Basic) | -$0.07 | — | -133.3% |
| EPS (Diluted) | -$0.07 | — | -133.3% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Current Assets | $1.2M | -32.5% | — |
| Total Assets | $1.3M | -29.7% | — |
| Current Liabilities | $2.9M | -72.8% | — |
| Total Liabilities | $3.0M | -72.1% | — |
| Stockholders' Equity | -$1.6M | +81.3% | +91.4% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$9.6M | — | — |
| Capital Expenditures | $13K | — | — |
| Investing Cash Flow | -$788K | — | — |
| Financing Cash Flow | $11.0M | — | — |
| Free Cash Flow | -$9.6M | — | — |